Premium
MINIMAL RESIDUAL DISEASE (MRD) IN EARLY STAGE FOLLICULAR LYMPHOMA CAN PREDICT PROGNOSIS AND DRIVE RITUXIMAB TREATMENT AFTER RADIOTHERAPY
Author(s) -
Pulsoni A.,
Della Starza I.,
Cappelli L.V.,
Tosti M.E.,
Annechini G.,
Cavalli M.,
De Novi L.A.,
D'Elia G.M.,
Grapulin L.,
Guarini A.,
Del Giudice I.,
Foa' R.
Publication year - 2017
Publication title -
hematological oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.918
H-Index - 44
eISSN - 1099-1069
pISSN - 0278-0232
DOI - 10.1002/hon.2438_87
Subject(s) - medicine , rituximab , minimal residual disease , stage (stratigraphy) , follicular lymphoma , oncology , gastroenterology , bone marrow , lymphoma , radiation therapy , paleontology , biology
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom